Meptazinol
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Meptazinol: From Analgesia to Insomnia
One-Sentence Summary
Meptazinol is a partial mu-opioid receptor agonist analgesic, originally used for moderate to severe pain (e.g. postoperative, obstetric). The TxGNN model predicts it may be effective for Insomnia, but currently no clinical trials or published literature support this specific indication — the prediction score alone drives this ranking.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Insomnia (disease) |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L5 (model prediction only) |
| UK Market Status | Not marketed — no licences on file |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Note: No original approved-indication text is available in the regulatory data provided (licences list is empty). Class-level pharmacology (opioid analgesic) is used for context below.
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for Meptazinol. Based on known pharmacological classification, it is a partial mu-opioid receptor agonist analgesic, historically used for moderate to severe pain including postoperative and premedication settings. Opioids are well known to produce central nervous system sedation, which is the presumed (but unverified) basis for the TxGNN model linking Meptazinol to insomnia.
However, this mechanistic rationale is inferred purely from drug-class characteristics rather than from any direct study of Meptazinol in sleep disorders. Of the ten TxGNN-predicted indications in this evidence pack, only one — anxiety (ranked 5th, score 96.0%) — has any supporting literature at all, consisting of three older studies (1982–1986) describing sedative and premedication effects. The top-ranked prediction, insomnia, has no clinical trial or literature evidence whatsoever, meaning the mechanistic plausibility described above remains speculative and should not be treated as validated.
Given the absence of a confirmed original indication, missing MOA data, and no safety/warning information, this candidate sits at an early, largely theoretical stage of evaluation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
No marketing authorisations are on file for Meptazinol; the drug is not currently marketed in the UK.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (insomnia) has no clinical trial or literature support (Evidence Level L5), and critical drug-level data — mechanism of action and product labelling warnings/contraindications — are both flagged as data gaps, one of which (labelling) is a blocking gap that prevents any initial safety assessment (S1). The drug is also not currently marketed in the UK, with no licence records available.
To proceed, the following is needed:
- Product labelling/SmPC warnings and contraindications (currently blocking gap, DG001)
- Confirmed mechanism of action data (DG002)
- Confirmed original approved indication(s) for regulatory context
- Any preclinical or mechanistic literature specifically linking Meptazinol to sleep disorders
- If pursuing further research, the anxiety indication (L4, three historical studies) is the only candidate among the ten with any evidentiary basis and may warrant a scoping review before insomnia is prioritised
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.